Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.


Trial Name: Randomized Phase II Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma.

Protocol ID: E1412


  • Age > 18 years
  • Histologically confirmed Diffuse Large B Cell Lymphoma (DLBCL) expressing CD20 antigen. 
  • Previously untreated and not receiving any other agent that would be considered as a treatment for the lymphoma.
  • Must meet required laboratory values
  • Absence of history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia.  Patients with a history of deep vein thrombosis/embolism/thrombophilia may participate if they are on full anticoagulation during the treatment.
  • No other active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy.  Exceptions to this are as follows: localized nonmelanotic skin cancer and any cancer that in the judgment of the investigator has been treated with curative intent and will not interfere with the study treatment plan and response assessment.
  • Women must not be pregnant or breast-feeding because this study involves an investigational agent that the effects on the developing fetus and newborn are unknown.
  • Females of childbearing potential must have a negative pregnancy test prior to and again within 24 hours of starting lenalidomide.

Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy.

Enrollment: 220 will be enrolled


Taking part in this study may or may not make your health better.  While doctors hope that the addition of lenalidomide will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about lenalidomide combined with chemotherapy as a treatment for cancer.  This information could help future cancer patients.


These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Feb 24, 2014

Updated: Oct 16, 2014

« Return to Trials